Conclusions: In LMCA stenosis without significant aorto-ostial stenosis, both strategies of with or without aorto-ostial coverage showed similar clinical outcomes at 2 years.

TCT-224

Trends in Revascularization Strategy and Outcomes in Left Main Stenosis: Data from ASAN MAIN Registry

Seung-Jung Park1, Jung-Min Ahn1, Se-Hun Kang1, Hee-Soon Park1, Sung-Soo Cheon1, Min Su Kim1, Young-Hak Kim1, Suno Nakamura1, 2, Young-Hak Kim1, Cheol Whan Lee1, Seung-Wook Park1, 2

Background: Changes in revascularization strategies and outcomes among patients with significant unprotected left main coronary artery (LMCA) stenosis remain largely unknown.

Methods: A total of 2618 consecutive patients with LMCA stenosis undergoing revascularization treatment between 1995 and 2010 were identified from ASAN MAIN registry. Patients were classified into three periods: bare metal stent (WAVE1) period (1995-1998), early drug-eluting stent (WAVE2) period (2003-2006), and late drug-eluting stents (WAVE3) period (2007-2010). The major adverse cerebro-cardiovascular events (MACCE) were defined as death, myocardial infarction, repeat revascularization, or stroke at 2-years.

Results: The major adverse cerebro-cardiovascular events (MACCE) were defined as death, myocardial infarction, repeat revascularization, or stroke at 2-years. During study periods, 1124 patients underwent percutaneous coronary intervention (PCI) with stent and 1494 patients underwent coronary artery bypass grafting (CABG). The proportion of PCI significantly increased from 35% to 52%. Among patients receiving PCI, the risk-adjusted incidence rate of MACCE decreased from 20.18 cases per 100 person-years in WAVE1 to 6.77 cases per 100 person-years in WAVE3 (P< 0.001 for trend). Death, the composite of death, myocardial infarction, and stroke, or repeat revascularization was also significantly decreased by 40%, 35%, and 46%, respectively. However, among patients receiving CABG, the risk-adjusted incidence rate of MACCE was not significantly changed during study period. In addition, the difference in the risk of MACCE between PCI and CABG progressively reduced (adjusted hazard ratio [95% confidence interval]: 0.33 [0.23-0.47], 0.53 [0.35-0.80], and 1.01 [0.68-1.49] from WAVE1 through WAVE3.

Conclusions: The outcomes of PCI for LMCA stenosis have significantly improved and PCI has successfully substituted CABG in a significant proportion of patients with LMCA stenosis.

TCT-225

Dedicated Bifurcation BioOSS® Stent In The Treatment Of Distal Left Main Stem Stenosis – International Registry

Jack Biel1, Robert J. Gill1, Dobrin Vassilev1, Luis A. Iñigo-García1, Leticia Fernandez Lopez1, Tomasz Pawlewski1, 2

1Central Clinical Hospital of the Ministry of the Interior, Warsaw, Poland, 2Institute of Experimental and Clinical Medicine, Polish Academy of Science, Warsaw, Poland, National Heart Hospital, Sofia, Bulgaria, 3Hospital Costa del Sol, Marbella, Málaga, 4Hospital Costa del Sol, Marbella, Málaga

Background: The aim of this study was to assess efficacy and safety profile of distal LM stenosis treatment with dedicated bifurcation BioOSS stents (Balton, Poland) in group I - paclitaxel-eluting BioOSS Expert® and in group II - sirolimus-eluting BioOSS LIMs.

Methods: Patients with CAD or NSTE-ACS were enrolled between January 2011 and June 2013 in three centers in Bulgaria, Poland and Spain. Decision for LM stenting was based on Heart Team consensus. Provisional T-stenting was default strategy. Contiguous angiography was planned at 12 months in all patients. The primary end point is MACCE at 12 months. Here, we present 6-month clinical data from both groups and completed angiographic data from BioOSS Expert. At the time of TCT 2014 angiographic data from BioOSS LIM will be completed.

Results: There were enrolled 158 patients (65 in BioOSS Expert group and 96 in BioOSS LIM group). The average age was 65.7±12.5 yrs and 19.7% were female. In the study 17.8% of patients were with NSTE-ACS, 34.1% with hypertension, 32.1% with diabetes, 39.2% with prior MI, 43.3% with prior PCI and 17.4% with prior CABG. The mean SYNTAX score was 21.52±6.58. True bifurcations were treated in 70.1% of cases. All BioOSS® stents were implanted successfully. The nominal stent parameters were as follows: BioOSS Expert group: 4.07±0.26mm (proximal diameter) x 3.36±0.26mm (distal diameter) x 16.61±1.72 mm (length) and BioOSS LIM group: 3.90±0.24mm x 3.17±0.39mm x 16.8±2.06mm. Classical DES in side branch was implanted in 25.9% and 21.4%, respectively. Almost 62% of procedures were done from radial access and 85% with 6F catheter. After 12 months in BioOSS Expert group angiographically-driven TLR rate was 9.6%, whereas clinically-driven TLR was 3.2%. In BioOSS LIM group data are pending - at 6 months there were no death or MI. In BioOSS Expert group late lumen loss was as follows: in main vessel - 0.21±0.1mm, in main branch - 0.26±0.12mm and in side branch - 0.14±0.09mm.

Conclusions: Dedicated bifurcation BioOSS stents seem feasible devices with promising effectiveness and safety profile in distal LM stenosis. Complete BioOSS LIM data facilitate to answer the question if the used drug or stent design is more crucial.

TCT-226

Impact of Final Kissing Balloon Inflation Following Single-stent Strategy in Unprotected Left Main Lesion

Yasuke Watanabe1, Kensuke Takagi2, Sunao Nakamura1

1New Tokyo Hospital, Matsudo, Japan, 2New-Tokyo Hospital, Japan, Matsudo, Japan, 4Hospital Costa del Sol, Marbella, Málaga

Background: Final kissing balloon inflation (FKBI) is a mandatory technique in unprotected left main (ULM) revascularization with 2-stent strategy. However, there is no consensus regarding the necessity of FKBI in single-stent strategy. Therefore, to assess the need of FKBI for single-stent strategy in ULM lesion, we compared clinical outcome between patients treated using single-stent strategy with FKBI and those without FKBI.

Methods: A total of 654 consecutive patients who had ULM lesion were treated using single-stent strategy. In patients using single-stent strategy, 357 patients were proceeded with FKBI (FKBI group) and 113 patients were without FKBI (no-FKBI group). The end point of this study is the occurrence of Major Adverse Cardiovascular Event (MACE) defined as composites of all cause death, target lesion revascularization (TLR) and MI. Furthermore, overall TLR, TLR for main branch (TLR-MB) involving ULM to left anterior descending artery and TLR for side branch alone (TLR-SB) involving left circumflex (LCx) at 1-year were evaluated.

Results: Patient and lesion characteristics were similar between the 2 groups. Following single-stent strategy, 36 patients (8.9%) necessitated an additional bailout stenting for ostial LCx stenosis. In the total population, the occurrence of MACE at 1 year is similar between the two groups (7.4% in the FKBI group and 11.9% in the no FKBI group. log rank p=0.112). The incidences of overall TLR, TLR-MB and TLR-SB at 1 year were also similar between FKBI group vs. no-FKBI group (7.0% vs. 9.3%, 4.4% vs. 4.2% vs. 4.7%, p=0.24 and 5.0% vs. 5.6%, p=0.31, respectively).

Conclusions: Single-stent for ULM disease was feasible at mid-term follow-up. However, FKBI had no impact on clinical outcome following ULM revascularization with Single-stent strategy.

TCT-227

Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for Unprotected Left Main Stenosis with Severe Left Ventricular Dysfunction: Data from ASAN MAIN Registry

Min Su Kim1, Jung-Min Ahn1, Hee-Soon Park1, Se-Hun Kang1, Suno Nakamura1, Byeong Joo Bae1, Jae Hyung Roh1, Hyn Woo Park1, Mineok Chang1, Sang-Han Yoon1, Joon Young Lee1, Duk-Woo Park1, Soo-Jin Kang1, Seung-Whan Lee1, Young-Hak Kim1, Cheol Whan Lee1, Seung-Wook Park1, Seung-Jung Park1

1Asan Medical Center, Seoul, Korea, Republic of

Background: Unprotected left main coronary artery (ULMCA) stenting has been investigated as an alternative to coronary artery bypass grafting (CABG). However, long-term benefits of PCI or CABG in patients with ULMCA disease and severe left ventricular dysfunction (LVD) have not been established.

Methods: Between March 1992 to February 2011, a total of 213 patients with significant ULMCA disease and severe LVD (ejection fraction [EF] of 40% or less) who underwent PCI (42 patients) or CABG (171 patients) were identified from ASAN MAIN Registry. Primary endpoint was all-cause death at 2 years.